| abstract |
The invention relates to the use of a virus, preferably an adenovirus, for the production of a medicament or for replication in cells. Said virus is replication-deficient in cells which do not contain YB-1 in the core while coding for an oncogene or oncogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP. The oncogene protein represents the viral oncogene protein E1A which is mutated, for example. Said medicament is used particularly for treating tumors showing multiple resistance against cytostatic drugs. |